Views: 1,293 | Downloads:
18
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Epithelial Ovarian Cancer Treated by Platinum or Platinum Analogue with Cyclophosphamide : Experience in Ramathibodi Hospital
Linasmita V 
,
Wilailak S ,
Srisupundit S ,
Tangtrakul S ,
Bullangpoti S ,
lsrangura N
,
Wilailak S ,
Srisupundit S ,
Tangtrakul S ,
Bullangpoti S ,
lsrangura N This study presented the outcome of 92 EOC patients treated by platinum or platinum
analogue with cyclophosphamide from January 1, 1993 to December 31, 1995. There were 77
evaluable patients. The follow-up ranged from 4 - 42 months (median 14 months). The over all
3-year survival was 64 per cent and the median progression-free interval was 16 months for the
whole group. There was no significant difference in survival between patients who received cisplatin
and those who received carboplatin (P=0.093). Patients who underwent optimal debulking
surgery had significantly longer progression-free interval (P=O.OOl) than those who had suboptimal
surgery. Fifty four per cent of patients with clear cell carcinoma died of the disease.
Patients who received cisplatin had a drop out rate while on therapy more often (24% vs 5.3%)
than that of carboplatin. Toxicities from chemotherapy were moderate but manageable.
analogue with cyclophosphamide from January 1, 1993 to December 31, 1995. There were 77
evaluable patients. The follow-up ranged from 4 - 42 months (median 14 months). The over all
3-year survival was 64 per cent and the median progression-free interval was 16 months for the
whole group. There was no significant difference in survival between patients who received cisplatin
and those who received carboplatin (P=0.093). Patients who underwent optimal debulking
surgery had significantly longer progression-free interval (P=O.OOl) than those who had suboptimal
surgery. Fifty four per cent of patients with clear cell carcinoma died of the disease.
Patients who received cisplatin had a drop out rate while on therapy more often (24% vs 5.3%)
than that of carboplatin. Toxicities from chemotherapy were moderate but manageable.
Download:
PDF